IJBPAS, December, 2022, 11(12): 6060-6070

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

FOOD AND DRUG LAWS AFFECTING PHARMACEUTICAL PRODUCT DESIGN, DEVELOPMENT AND COMMERCIAL MANUFACTURING

NADELLA SC[1*], THALLA S[2], KOUSHIK Y[1] AND NADENDLA RR[1]

1: Department of Pharmaceutical Regulatory Affairs, Chalapathi Institute of Pharmaceutical Sciences (Autonomous), Lam, Guntur, Andhra Pradesh, India

2: Department of Pharmacology, Chalapathi Institute of Pharmaceutical Sciences (Autonomous), Lam, Guntur, Andhra Pradesh, India

***Corresponding Author: Ms. Nadella Sarath Chandrika: E Mail: chandrikanadella1746@gmail.com**

Received 26th Jan. 2021; Revised 25th Jan. 2022; Accepted 12th March 2022; Available online 1st Dec. 2022

https://doi.org/10.31032/IJBPAS/2022/11.12.6690

ABSTRACT

Every country has its own set of laws and regulations governing pharmaceutical products; these restrictions are nearly identical with minor variances. Failure of a drug at any step, from discovery to development to marketing, results in a significant loss, not only financially and in terms of the organization's reputation, but also in terms of public health. Any company that wants to sell its products to a specific government agency should have a thorough understanding of the rules and regulations, though regulatory authorities can provide strategic counsel in the case of extremely harsh judgments. A company's regulatory department must eliminate the risk by displaying clinically safe and effective drug items properly. They must also accept responsibility for producing high-quality drug items in accordance with rules. The regulatory department serves as a link between the country's regulatory authorities and the Rising populations due to low death rates, as well as a focus on the development of cutting-edge drugs, are predicted to accelerate market development in pharmerging countries. China, Russia, and India are likely to hold a significant portion of the pharmaceutical market among the 17 most important pharmerging countries. To appreciate the profile of pharmerging countries, special

evaluation processes was industrialized, and let us use the examples of Brazil, India, China, the United States, and some European countries to understand the current trend. According to a study, the percentage organization's numerous departments. It occurs during every stage of a drug's development, as well as after approval and during commercialization.

Keywords: Pharmaceutical Product Design, Development, and Commercial Manufacturing, development of generic drugs History, approval of new drug

INTRODUCTION:

This chapter provides an overview of the regulatory landscape for regulatory bodies, highlighting how various regulations influence various areas of drug development. This chapter also discusses significant regulatory concerns that pharmaceutical manufacturers and sponsors consider during the development and commercialization of a new drug or therapy. Product design is a preparatory experimental exercise that every industry must complete in order to generate durable and acceptable products. It is the execution of ideas through a systematic procedure **[1]** that results in a satisfactory product. Pharmaceutical items are conceived and manufactured with certain compendial constraints in mind, and they are governed by the laws of various country constitutions that have been established after thorough testing. Almost every country has its own regulatory authority in charge of enforcing laws and regulations and issuing recommendations for drug development, registration, licensing, manufacture, labeling, and marketing of pharmaceutical products. Aside from national regulatory authorities, worldwide organizations are aiming to improve medication safety by developing recommendations for drug approval and product development In addition to national regulatory bodies, international organizations are trying to improve medication safety by developing guidelines for drug approval, product manufacturing, drug distribution, drug price control, advertising and marketing, and intellectual property rights protection. The regulatory agencies of many countries are covered exhaustively in this book for the readers' quick and easy reference. Drug regulation encourages a variety of activities to ensure drug safety, efficacy, and quality. The pharmaceutical company must build its own regulatory affairs in order to comply with the regulations. From clinical research to marketing and post-marketing surveillance, this department is involved in every stage of medication development. It serves as a link between the pharmaceutical

sector and the regulatory agencies that oversee drug approval. Pharmaceutical companies are always up against worldwide competition, and they must launch their products on time, on budget, and according to specifications. These three important restrictions are governed by rules and regulations, and they represent a product's success or failure. After the steps of drug discovery and development are completed, commercial manufacturing begins according to predetermined standards that are periodically inspected by the authority where these products are envisioned to be offered **[1]**.

Pharmaceutical product development:

A quality by design approach



Figure 1: Quality by design system



Figure 2: Pharmaceutical quality systems for quality by design

Product design and development

The important features for pharmaceutical development are determined by the active pharmaceutical ingredient's (API) physicochemical and pharmacological properties. The goals of the QbD product development programme are to meet desired patient needs and to identify characteristics that a medicinal product should have in order to exert the intended therapeutic response. To meet these predetermined goals, product development must always be systematic, scientific, and risk-based. At various stages of this holistic approach, the experience component is an add-on value. The application of correct statistical methodologies such as design of trials, adequate RA, and management tools can result in a successful and knowledge-based product development. Furthermore, understanding CQA aids in the development of meaningful and adaptable regulatory products **[2]**.

Design objectives for pharmaceutical quality

Pharmaceutical Quality by Design (QbD) is a systematic method to development that starts with established goals and stresses product and process understanding and control based on strong science and risk management. The following are examples of pharmaceutical QbD objectives:

1. To develop meaningful product quality criteria based on clinical results.
2. To improve product and process design, understanding, and control in order to improve process capability and reduce product variability and defects.
3. To improve the efficiency of product development and production

4. To improve root cause analysis and change management after approval

5. Process competence and development on a continuous basis

Quality Target Product Profile that Identifies the Drug Product's Critical Quality Attributes

The QTPP is a prospective summary of the quality features of a drug product that should be reached to assure the intended quality, while also considering the drug product's safety and efficacy. The QTPP serves as the foundation for the product's development. The following may be considered for inclusion in the QTPP: (e.g., dissolution and aerodynamic performance) appropriate for the drug product dosage form being developed **[3]**.

Drug Development for Developing Countries

Infectious and parasitic diseases accounted for more than half of all healthy years lost in Africa in 2002, but only 3% in industrialized nations. 1) Malaria, leishmaniasis, Chagas disease, tuberculosis, dengue fever, and African trypanosomiasis are among the communicable diseases that disproportionately impact individuals in impoverished nations. For many of these disorders, a lack of scientific information is not a substantial impediment to therapeutic development. Scientists know more about leishmania and trypanosome biology, immunology, and genetics than any other, The FDA gives drugs priority classification based on their apparent novelty. The United States developed fourteen of the twenty-nine "blockbuster drugs" (those with sales of $1 billion or more) in the 1990s. Companies worth more than $1 billion in their fifth year on the market were given priority (Exhibit 1). Zocor (simvastatin) for cholesterol and Norvasc (amlodipine) for hypertension are two medications that were not given priority review yet went on to become market leaders **[4]**.

The FDA's New "Breakthrough Therapy" Designation Speeds Up Drug Development

Many people suffering from serious or life-threatening conditions for whom there are no appropriate treatments are understandably eager to get their hands on novel treatments, and are ready to trade greater certainty regarding a drug's performance for faster access. Because a typical clinical drug development programme takes around 7 years and generates a large body of safety and efficacy data, the Food and Drug Administration (FDA) has long had expedited paths available for medications being researched for such disorders **[5]**.

Process of drug development

From discovery to market, the drug development process is lengthy and expensive. During clinical trials, stringent procedures are in place to protect study participants' safety while also ensuring that all adverse event data is collected.

Preclinical evaluation

A medication must go through a long set of laboratory and animal studies before being investigated in people to determine its therapeutic and harmful effects. Preclinical research is also used to characterize the drug's pharmacokinetics and pharmacodynamics, which include absorption, distribution, metabolism, excretion, and pharmacological impact persistence. In vitro and in vivo studies in animals are used to look for unanticipated pharmacological and toxic effects at the whole-animal level as well as on individual organs and tissues in the preclinical stage.

Study and Clinical Testing Application

Manufacturers must petition the US Food and Drug Administration (FDA) to study investigational medications or new indications or dosages for approved drugs, according to US law. This procedure ensures that the FDA can alert sponsors and investigators about potentially dangerous medication uses before human studies begin. Clinical trials of experimental medications are typically conducted in stages. Human volunteers in clinical trials are referred to as participants, and users of drugs outside of a research context are referred to as patients. event of interest, these studies can range in size from dozens to thousands of participants **[6]**.

Generic Drug Product and Reference Drug follows

. A generic drug product must be pharmaceutically identical to the applicable reference drug product in Australia, Brazil, Chinese Taipei, Japan, Switzerland, and the United States. Pharmaceutical equivalents are defined as similar levels of the same active drug substance in the same dosage form and route of administration in the jurisdictions listed above. Although only Brazil expressly lists this as an additional need, the preferred reference product is generally the one offered domestically. In Australia, Canada, and Switzerland, it is permissible to use a reference product that has been approved and marketed outside of the country in restricted circumstances if certain strict conditions are met. Previously, pharmaceuticals were required in Mexico **[7]**.

Practical, Legal, and Ethical Issues with Investigational Drugs

The Food and Drug Administration (FDA) evaluates clinical trial data to determine if the

benefits of new treatments outweigh the hazards. This requirement, which was enacted in 19622, raised the threshold for approval and reduced the chances of new medications being ineffective or causing serious health concer. For the evaluation of goods that ultimately show to be safe and effective, developing such data regarding investigational drugs takes time. If there are no other treatments for the illness, the time lag can be an issue. As a result, the FDA devised an enhanced access programme to allow patients with critical illnesses to obtain investigational. The system of extended access has become increasingly divisive. Josh Hardy, a 7-year-old boy with a life-threatening infection, recently sought an experimental antiviral medicine called brincidofovir, which was suggested by his doctors. The drug's producer promised to include him in a newly formed open-label research after the media brought attention to his plight. In the context of the treatment or prevention of Ebola virus disease, which is typically fatal and for which no clearly effective pharmaceuticals or vaccines exist, the subject of making experimental drugs or vaccines available has also come up in public discourse. Thousands of patients each year seek access to incompletely researched medicines in order to extend their treatment options, but not all of them are successful. The practical, legal, and ethical challenges surrounding increasing access and usage of experimental medications are discussed. Medications prior to formal product approval.

Legal Challenges

The inability to get investigational medications has resulted in three types of legal issues. For starters, some patients have expressed their dissatisfaction with the current system. If the FDA regulates their capacity to acquire pharmaceuticals at any stage of development, it is violating their constitutional rights. In these instances, however, courts have generally held that there is no constitutional right of access. These three statutes demand that access be expanded.43The experimental treatment is recommended by the treating physician. Therapy, as well as the states of Colorado and Louisiana. The treating physician is also required by law. Evidence for the insufficiency of FDA-approved drugs. Alternatives to treatment ,Manufacturers and insurers are not obligated to supply and pay for experimental medicines.

Ethical Issues

Patients should have the right to alleviate acute suffering and enhance self-preservation, according to the major ethical

rationale for wider access, Expanded access proponents say that when the stakes are the highest, patients' anticipated capacity to make informed treatment decisions should be given the most weight [i.e., when death is likely or certain]The last scenario is widespread use under a treatment plan, such as what would happen after a successful study of an experimental medication is completed but before FDA approval **[8]**.

Novel Approaches in Drug Design

Drug design methodologies, as well as new drug discoveries in chemical and biological research, are the focus of novel approaches in drug design and development research. Various methodologies employed in the medication design and development process are reflected in my research. Structure-based drug design • Analog drug design • Combinatorial chemistry • Computational chemistry • Array technology • Pharmacogenomics • Combinatorial Chemistry • Proteomics • Recombinant DNA technology, and so on. METHODS • Recombinant DNA technology • Array technology • Pharmacogenomics • Combinatorial Chemistry • Proteomics **[9]**.

Pharmaceutical Product Development: Quality by Design:

The regulatory authorities and the pharmaceutical industry are both focusing on the scientific approach to quality by design (QbD) in the production of pharmaceutical products. It is a proactive, scientific, and risk-mitigation-based systematic method to improving pharmaceutical product quality standards. QbD contributes to the development of pharmaceutical products in the following ways:

1) Quality-target product profile (QTPP): The QTPP includes the desired target profile or requirements for the product based on quality attributes and market demand to assure safety, efficacy, quality, and patient compliance.

2) Critical material attributes (CMAs): CMAs of the active component and any excipients that will be used in the formulation. Each excipient has a distinct function or role in the formulation that adds to product performance.

3**) Design of the experiment (DOE):** During formulation development, DOE is planned, taking into account all independent and dependent elements in order to arrive at the best formulation statistically.

4) Failure mode effect analysis (FMEA): Before scaling up pharmaceutical items, FMEA is performed. High-risk factors are lowered to medium or low risk, and low-risk factors are mitigated by putting in place

appropriate controls for each high or medium risk factor.

5) Critical quality attributes (CQAs): During product development, the CQAs and their requirements are analyzed and inferred, then completed and submitted to regulatory agencies as the finished product specification for exhibit batches and commercial batches release and shelf-life. This ensures a consistently high-quality, high-performance product **[10]**.

CONCLUSION

The process of gaining approval for a drug is complex and lengthy. Because pharmaceuticals deal directly with the health of patients, there must be no compromise in drug quality. Although public health appears to be a simple goal, it is actually quite complicated. Numerous regulatory agencies are bound by various laws that directly or indirectly control medication development and manufacturing. The medication regulatory affairs department serves as a barrier between the pharmaceutical business and regulatory bodies, ensuring that all rules and regulations are followed. Drug safety, efficacy, purpose, quality, risk, and benefits are the fundamental concepts of drug regulatory departments, which can be regarded the backbone of the pharmaceutical sector. When research scientists are working on novel discoveries and conclusions, the regulatory affairs department is working on the foundational paperwork for the innovative research to be conducted. Drug approval is a lengthy process, and regulatory organisations scrutinise each stage, from chemistry to manufacturing to preclinical and clinical research. Regulatory authorities monitor licenced pharmaceuticals even after they have been approved, and if they are discovered to be unsuitable, they might be pulled from the market. During medication development, investigators and pharmaceutical corporations must consider the product's safety, efficacy, and quality, as well as the health of patients. The success of a pharmaceutical company is closely connected to the frequency with which new products are launched after approval Launching a new product has benefits as well as risks; if the product is fantastic, it will benefit the firm; but, if the product fails to gain approval or is recalled from the market, the company will suffer significant financial, reputational, and confidence losses. However, these losses are minor in comparison to human health and life, thus regulatory authorities are working efficiently and requiring pharmaceutical corporations to observe laws and regulations. Personnel in charge of regulatory affairs play a critical

role in directing medication development strategy. Regulatory affairs contributes to the overall success of drug development at all stages, from conception to post-market surveillance.

Acknowledgements

We acknowledge Chalapathi institute of pharmaceutical sciences for their support.

Conflict of Interest

There is no conflict of interest.

Funding

Nil

Ethics Statement

Not applicable

Informed Consent

Not applicable

REFERENCES:

[1] Akhilesh Tiwari, Megha Joshi, Sanyam Gandhi, Shantanu Bandopadhyay, Rakesh K. Tekade Food and Drug Laws Affecting Pharmaceutical Product Design, Development, and Commercial manufacturing science direct Vol 2, 2018, page no: 591-619, https://www.sciencedirect.com/science/article/pii/B9780128144213000178

[2] Kannissery Pramod, M. Abu Tahir, Naseem A. Charoo, Shahid H. Ansari, Javed Ali Pharmaceutical product development: A quality by design approach" *International journal of pharmaceutical investigation* vol. 6,3 (2016), Pageno129–138. https://www.ncbi.nl/pmc/articles/PMC4991121/

[3] Lawrence X. Yu, Gregory Amidon, Mansoor A. Khan, Stephen W. Hoag, James Polli, G. K. Raju and Janet Woodcock Understanding Pharmaceutical Quality by Design. *The AAPS journal* vol. 16,4 (2014), pageno: 83-771 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070262/

[4] David B. Ridley, Henry G. Grabowski, and Jeffrey L. Moe Developing Drugs For Developing Countries, Health Affairs, vol. 25, 2005, page no: 313–324; https://www.kidsvcancer.org/wp-content/uploads/2014/03/ridleys-original-article.pdf

[5] Rachel E. Sherman, M.D., M.P.H., Jun Li, J.D., Ph.D., Stephanie Shapley, M.B.A., Expediting Drug Development — The FDA's New "Breakthrough Therapy" Designation The New England Journal of Medicine vol11, 2013 page no: 1877-1880.

https://www.nejm.org/doi/pdf/10.1056/NEJMp1311439

[6] Jesse A. Berlin, ScD, Susan C. Glasser, PhD, and Susan S. Ellenberg, PhD Adverse event detection in drug development: recommendations and obligations beyond phase 3 ase 3. Am J Public Health, vol Aug; 98(8) 2008, page no. 71-1366. https://pubmed.ncbi.nlm.nih.gov/18556607/

[7] Barbara Davit, April C. Braddy, Dale P. Conner and Lawrence X. Yu. International Guidelines for Bioequivalence of Systemically Available Orally Administered Generic Drug Products: A Survey of Similarities and Differences. The AAPS Journal, Vol. 15, No. 4, October 2013 page no:974-990 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787230/pdf/12248_2013_Article_9499.pdf

[8] Jonathan J. Darrow, S.J.D., J.D., M.B.A., Ameet Sarpatwari, J.D., Ph.D., Jerry Avorn, M.D. and Aaron S. Kesselheim, M.D., J.D., M.P.H Health Law, Ethics, and Human Rights Practical, Legal, and Ethical Issues in Expanded Access to Investigational Drugs, The new england journal of medicine, vol 372;3,2015,pageno: 279-286 https://www.nejm.org/doi/pdf/10.1056/nejmhle1409465

[9] Subash Senthil, T Malathi1, M Surendrakumar1Novel Approaches in Drug Design. Journal of Develop Drugs, vol 10,2021 page no 1-4https://www.longdom.org/open-access/novel-approaches-in-drug-design.pdf

[10] Suhani Sinha, Rohit Dutt and Rahul Pratap Singh, Quality by Design in Pharmaceutical Product Development, Acta Scientific Pharmaceutical Sciences, Vo1-3, 2019, page no. 70-72. https://www.actascientific.com/ASPS/pdf/ASPS-03-0192.pdf